Wedbush Reiterates Sangamo BioSciences Outperform, $9 FVE

Wedbush reiterated its Sangamo BioSciences SGMO Outperform rating and fair value estimate of $9 in a research report published today. In the report, Wedbush states, "Sangamo has sufficient cash runway through important clinical and strategic milestones in 2012 including Phase 1/2 data for SB-728-T treatment of HIV/AIDS, the initiation of two additional clinical trials of SB-728-T (H1:12), and clarity on a potential clinical candidate from the ZFN program in monogenic diseases." Shares of Sangamo BioSciences were trading at $2.72 at the time of posting, up 3.38% from Monday's market close.